Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesSanthera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG

PortfolioPortfolio WatchlistWatchlist
Company price
14.94 GBX 0.86 ( 6.11%)
Last update at 2026-10-27T16:20:00Z
VOLUME
1793
Market Cap
189.52M

Momentum Score

…

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
14.58
Low
14.98
High
52 Week Price Range
9.50
Low
17.74
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
14.08
Dividend Yield
-
Revenue TTM
49.02M
Revenue Per Share
4.05
Gross Profit TTM
6.57M
Debt / Equity
1.49
ROE
-288.14%
Net Debt
0.25M
ROCE
-20.25%
Diluted EPS TTM
-1.63

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -41.66M 54.82M -70.62M -54.72M -67.46M
Net income -41.97M 54.78M -71.08M -55.53M -67.66M
Selling general administrative 19.48M 21.18M 14.56M 12.72M 12.44M
Selling and marketing expenses 11.02M 9.78M 10.86M 9.33M 11.47M
Gross profit 22.96M 100.18M 3.88M -5.36M 4.58M
Ebit -21.53M 76.13M -45.77M -56.89M -53.08M
Ebitda -15.89M 79.17M -42.56M -53.59M -49.62M
Depreciation and amortization 5.65M 3.04M 3.21M 3.30M 3.46M
Operating income -33.38M 68.84M -45.77M -56.89M -53.08M
Other operating expenses 72.50M 34.57M 57.90M 36.70M 75.58M
Interest expense 20.17M 21.31M - 0.00M 0.00M
Tax provision - - - - 0.20M
Interest income - - - - 6.12M
Income tax expense 0.31M 0.04M 0.46M 0.81M 0.20M
Total revenue 39.12M 103.41M 7.47M -1.59M 15.01M
Total operating expenses 56.69M 31.34M 54.31M 32.93M 65.14M
Cost of revenue 15.53M 3.23M 3.59M 3.77M 10.43M
Total other income expense net -8.28M -14.02M -24.85M 2.17M -14.38M
Net income applicable to common shares - - - -55.53M -67.66M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 152.49M 109.63M 63.73M 91.12M 88.69M
Intangible assets 68.95M 73.97M 59.21M 64.60M 67.67M
Other current assets 3.48M 2.04M 1.17M 2.04M 2.51M
Total liab 124.79M 49.69M 107.41M 89.79M 95.04M
Total stockholder equity 27.70M 59.94M -43.69M 1.33M -6.35M
Other current liab 29.36M 19.06M 45.52M 30.37M 25.27M
Common stock 1.34M 1.26M 0.75M 54.61M 19.43M
Retained earnings -614.69M -572.72M -627.50M -556.42M -500.90M
Other liab - - 36.31M 30.01M 6.17M
Other assets - - 0.00M 0.09M 0.84M
Cash 40.92M 30.37M 1.35M 21.21M 12.41M
Total current liabilities 46.14M 44.31M 49.41M 32.78M 29.07M
Current deferred revenue 0.06M 0.18M - - -
Net debt 0.25M -7.34M -1.35M -21.21M -12.41M
Short term debt 7.50M 21.51M - - 10.60M
Short long term debt total 41.17M 23.03M - - 59.80M
Other stockholder equity 641.05M 631.40M 583.06M 503.14M 475.12M
Property plant equipment - - - 1.32M 1.90M
Total current assets 75.81M 34.66M 3.06M 24.64M 17.72M
Net tangible assets - - -101.96M -63.27M -74.03M
Net receivables 13.88M 0.44M 0.44M 0.96M 2.32M
Long term debt - - - - 57.88M
Inventory 17.53M 1.81M 0.11M 0.43M 0.48M
Accounts payable 9.22M 3.56M 3.90M 2.41M 3.80M
Accumulated other comprehensive income -3.30M 1.01M - - -
Treasury stock - - - - -1.58M
Non currrent assets other - 73.97M -60.66M -66.39M -70.13M
Non current assets total 76.67M 74.97M 60.66M 66.39M 70.13M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - 0.02M 0.08M 0.10M
Change to liabilities - - 0.00M 0.00M 0.00M
Total cashflows from investing activities -0.06M -18.04M - 0.07M 1.56M
Net borrowings - - - 31.55M 23.49M
Total cash from financing activities 46.08M -0.17M 13.99M 46.02M 23.15M
Change to operating activities - - - 1.77M 3.25M
Net income -41.97M 54.78M -71.08M -55.53M -67.66M
Change in cash 10.55M 29.02M -19.86M 8.80M -18.95M
Begin period cash flow 30.37M 1.35M 21.21M 12.41M 31.36M
End period cash flow 40.92M 30.37M 1.35M 21.21M 12.41M
Total cash from operating activities -35.53M 47.27M -29.84M -37.36M -43.51M
Depreciation 5.65M 3.04M 3.60M 3.67M 4.45M
Other cashflows from investing activities - -23.65M - - 1.50M
Sale purchase of stock - - - -0.06M -0.92M
Other cashflows from financing activities 24.59M -1.02M 33.09M 46.82M 25.14M
Change to netincome - - - 12.68M 16.33M
Capital expenditures 0.15M 23.74M 0.05M 0.00M 0.03M
Change in working capital -14.34M -5.28M - - 14.47M
Stock based compensation - 5.99M 5.49M 2.76M 3.03M
Other non cash items 15.14M -11.27M 32.13M 11.73M 16.67M
Free cash flow -35.68M 23.53M -29.90M -37.36M -43.54M

Peer Comparison*

Sector: Industry:

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
0QN1
Santhera Pharmaceuticals Holding AG		 0.86
6.11%		 14.94 - - 3.87 -
0R15
SoftBank Group Corp.		 248.00
5.84%		 4494.00 - - - -
0R1E
Nintendo Co. Ltd.		 -115.00
1.34%		 8476.00 - - - -
0LC3
Synchrony Financial		 2.34
3.20%		 75.60 0.09 - 4.97 -
0HQP
CBRE Group Inc. Cl A		 0.15
0.12%		 122.47 0.25 - 1.18 -

Profile*

Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.

Hohenrainstrasse 24, Pratteln, Switzerland, 4133

41 61 906 89 50

https://www.santhera.com

78

Name Title Year Born
Dr. Thomas Meier Ph.D. Founder & Chairman 1962
Mr. Dario Eklund Chief Exec. Officer 1968
Mr. Andrew P. Smith CGMA, FCMA Chief Financial Officer 1963
Mr. Marc Schrader Head of Technical Devel. & Operations NA
Ms. Eva Kalias Head of Investor Relations & Communications NA
Mr. Oliver Strub Exec. VP, Gen. Counsel & Sec. 1963
Mr. Neville Kodkani M.D. Head of Global Marketing & Partner Management NA
Ms. Sarah Holmes-Klotz Head of People & Culture NA
Mr. Günther Metz Ph.D. Head of Bus. Devel. & Exec. VP 1958
Mr. Shabir Hasham M.D. Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…